


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-5.65%
+3.34%
+0.64%
+0.45%
+0.19%
ARGX
argenx SE American
$918.92
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Chart
$836.39 (+9.87%)
$712.2 (+29.03%)
$543.48 (+69.08%)
$623.67 (+47.34%)
ARGX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

ARGX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ARGX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ARGX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is ARGX current stock price?
What are ARGX stock strengths?
What is ARGX Risk Level?
What is ARGX market cap and volume?
What is ARGX current Stock IQ?
Should I buy ARGX stock right now?
Is ARGX a Strong Buy right now?
What does a 'Strong Buy' rating mean for ARGX?
What does a 'Strong Sell' rating mean for ARGX?
What factors influence ARGX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-5.65%
+3.34%
+0.64%
+0.45%
+0.19%
ARGX
argenx SE American
Current Price
$918.92
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Chart
$836.39 (+9.87%)
$712.2 (+29.03%)
$543.48 (+69.08%)
$623.67 (+47.34%)
ARGX Analysts Opinion
ARGX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ARGX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ARGX Street Sentiment is extremely bullish and have positive views on the near-term outlook
ARGX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

Average key support and resistance price levels.
ARGX Latest Analysis
Guru Fundamental Report for ARGX - Benjamin Graham. Below is Valideas guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow ARGX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and
Thu Nov 20, 2025
argenx SE - Depositary Receipt (ARGX) Price Target Increased by 11.49% to 963.18. The average one-year price target for argenx SE - Depositary Receipt (NasdaqGS:ARGX) has been revised to $963.18 / share. This is an increase of 11.49% from the prior estimate of $863.91 dated November 9 2025. The price target is an average of many targets pr
Mon Nov 17, 2025
Heres Why argenx SE (ARGX) Rose in Q3. ClearBridge Investments an investment management company released its ClearBridge Mid Cap Strategy third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy stabilizing earnings and improved sentiment midcaps experienced growth in the third quarter. The Federal Reserves decision to cut rates helped small and mid-cap stocks [….]
Thu Nov 13, 2025
Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP . (RTTNews) - argenx SE (ARGX) Wednesday announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy.
Wed Nov 5, 2025
Piper Sandler Maintains argenx SE - Depositary Receipt (ARGX) Overweight Recommendation. Fintel reports that on November 4 2025 Piper Sandler maintained coverage of argenx SE - Depositary Receipt (NasdaqGS:ARGX) with a Overweight recommendation. Analyst Price Forecast Suggests 4.18% Upside
Wed Nov 5, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ARGX Stock trends
ARGX Stock performance
ARGX Stock analysis
ARGX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.